GlobeNewswire

Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
11/12/2025
Restructuring Supports RYTELO ® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Geron [...]
Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026
11/12/2025
EMBOLD data to serve as basis of efficacy and safety following discussion with the FDA BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical [...]
NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx
11/12/2025
NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-off NEXGEL will also receive a 5% global royalty in perpetuity on products sold using its [...]
Aligos Therapeutics Presents Positive Data at HEP-DART 2025
11/12/2025
Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Aligos [...]
Bionano Recaps Advances in Optical Genome Mapping Showcased at AMP 2025
11/12/2025
SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) participated in the Association for Molecular Pathology (AMP) Annual Meeting, held November 11-15, 2025 in Boston, MA. Key presentations at [...]
MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential
11/12/2025
CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- A recent round of open-market purchases marks another display of confidence as the small molecule telomere-targeting cancer therapy by MAIA Biotechnology, Inc. (NYSE American: [...]
ImmuneWalk Therapeutics Announces Positive Results from Phase 1 SAD/MAD Study of IW-601, a First-In-Class Therapeutic with Broad Potential in Inflammatory and Autoimmune Diseases
11/12/2025
Phase 1 Clinical Trial Met All Primary and Secondary Endpoints and Demonstrated Positive Safety, Pharmacokinetics, and Mechanistic Validation Clinical Data Build Upon Robust Preclinical Activity Seen in Multiple Models [...]
Ophirex Announces Business Update: Advances Toward Food and Drug Administration (FDA) Approval for Varespladib as Novel Oral Snakebite Treatment
11/12/2025
Company announces agreement with FDA on human approval pathway based on Animal Rule Varespladib has received FDA MUMS designation for treatment of snakebite in dogs Animal health leader Aaron Schacht joins Board of [...]
Stryker declares an $0.88 per share quarterly dividend
11/12/2025
Portage, Michigan, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable January 30, 2026, to shareholders of record at [...]
ViroMissile Announces First-in-Human Phase I Trial of IDOV-Immune for Advanced Solid Tumors
11/12/2025
Study examines the safety and early efficacy of an oncolytic virus via a single intravenous dose SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- ViroMissile , Inc., a cancer immunotherapy company pioneering the IDOV™ ( [...]
PatchMD Launches New Dopamine Support Patch for Natural Mood and Focus Support
11/12/2025
Original Vitamin Patch Pioneer Introduces Comprehensive Dopamine Precursor Formula Backed by Clinical Research Las Vegas, NV, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Introductory Pricing: $19.95 with 30% December Discount [...]
Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial
11/12/2025
Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden immune responses to personalized tumor neoantigens not present in the targeted immunotherapy 87% (13/15) of [...]
Carrick Therapeutics Announces Positive Results from Phase 2 Randomized Trial of Samuraciclib in Combination with Fulvestrant in Patients with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer
10/12/2025
Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene mutation Phase 2 results presented at 2025 San Antonio Breast Cancer Symposium BOSTON, Dec. 10, 2025 ( [...]
Tiny Health Celebrates 100,000 Tests Milestone, Expands from Baby Gut Health Pioneer to Longevity Innovator
10/12/2025
The microbiome startup powering preventive and personalized health launches new aging study and deepens partnerships with leading wellness and longevity programs AUSTIN, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Tiny [...]
Persephone Biosciences Announces Publication in Cell Host & Microbe Highlighting the Critical Need to Restore Bifidobacterium in the Infant Gut Microbiome
10/12/2025
- Evidence shows infant microbiome trajectories established in the first months of life persist, shaping immune function and allergy risk into childhood - - Targeted early-life probiotic interventions using B. infantis [...]
EssilorLuxottica joins forces with Fondazione Chips-IT to accelerate the future of smart eyewear
10/12/2025
EssilorLuxottica joins forces with Fondazione Chips-IT to accelerate the future of smart eyewear Paris, France (10 December 2025) – EssilorLuxottica announces it is joining forces with Fondazione Chips-IT, Italy’s [...]
EssilorLuxottica va collaborer avec la fondation Chips-IT pour accélérer dans les lunettes connectées
10/12/2025
EssilorLuxottica va collaborer avec la fondation Chips-IT pour accélérer dans les lunettes connectées Paris, France (10 décembre 2025) – EssilorLuxottica a annoncé aujourd'hui une collaboration avec la fondation Chips- [...]
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy
10/12/2025
Highly encouraging early data from the ongoing Phase 1b study evaluating investigational drug GNS561 with a MEK inhibitor (MEKi) in KRAS mutated cholangiocarcinoma (CCA), positioning this novel combination as a [...]
GENFIT : GNS561 montre une activité antitumorale prometteuse en combinaison thérapeutique
10/12/2025
Données préliminaires très encourageantes de l’étude de Phase 1b en cours évaluant le médicament expérimental GNS561 associé à un inhibiteur de MEK (MEKi) dans le cholangiocarcinome (CCA) avec mutation KRAS, [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum